Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-635-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2
Next Earnings Date4/15/2019 (Estimated)
OptionableNot Optionable
Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions
What is Mateon Therapeutics' stock symbol?
Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."
How were Mateon Therapeutics' earnings last quarter?
Mateon Therapeutics Inc (OTCMKTS:MATN) posted its earnings results on Wednesday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting analysts' consensus estimates of ($0.02). View Mateon Therapeutics' Earnings History.
When is Mateon Therapeutics' next earnings date?
What price target have analysts set for MATN?
1 brokers have issued twelve-month target prices for Mateon Therapeutics' shares. Their predictions range from $1.00 to $1.00. On average, they anticipate Mateon Therapeutics' stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 619.4% from the stock's current price. View Analyst Price Targets for Mateon Therapeutics.
What is the consensus analysts' recommendation for Mateon Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mateon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mateon Therapeutics.
Has Mateon Therapeutics been receiving favorable news coverage?
Headlines about MATN stock have trended positive on Friday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mateon Therapeutics earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of Mateon Therapeutics' key competitors?
Some companies that are related to Mateon Therapeutics include Windtree Therapeutics (WINT), TrovaGene (TROV), Vaxart (VXRT), aTyr Pharma (LIFE), Aevi Genomic Medicine (GNMX), Genetic Technologies (GENE), Mymetics (MYMX), Neuralstem (CUR), Enzon Pharmaceuticals (ENZN), Vitro Diagnostics (VODG), Gene Biotherapeutics (CRXM), Omni Bio Pharmaceutical (OMBP) and AveXis (AVXS).
What other stocks do shareholders of Mateon Therapeutics own?
Who are Mateon Therapeutics' key executives?
Mateon Therapeutics' management team includes the folowing people:
- Dr. William D. Schwieterman, Chairman, CEO & Pres (Age 61)
- Mr. Matthew M. Loar, Chief Financial Officer (Age 56)
- Ms. Shari Annes, Exec. Officer of Investor Relations
- Dr. Yuval Binur, Exec. VP of Financial
- Ms. Pamela Ha, Controller
How do I buy shares of Mateon Therapeutics?
Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mateon Therapeutics' stock price today?
One share of MATN stock can currently be purchased for approximately $0.1390.
How big of a company is Mateon Therapeutics?
Mateon Therapeutics has a market capitalization of $5.76 million. The biopharmaceutical company earns $-13,810,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Mateon Therapeutics employs 2 workers across the globe.
What is Mateon Therapeutics' official website?
How can I contact Mateon Therapeutics?
Mateon Therapeutics' mailing address is 701 GATEWAY BLVD SUITE 210, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]
MarketBeat Community Rating for Mateon Therapeutics (OTCMKTS MATN)
MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe MATN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MATN will underperform the S&P 500 over the long term. You may vote once every thirty days.
